Creative Biolabs is a forward-looking CRO company as well as a leading custom service provider in the field of T-cell therapy development. Equipped with a team of professional scientists, we can provide our clients with a variety of customized application platforms in T cell antigen connector (TAC) adoptive immunotherapy. We guarantee the finest results for our customers all over the world.
In our company, TAC has been designed by fully simulating the process of binding TCR and polypeptide-MHC molecules to form the first signal of natural T-cell activation. In general, it is made up of three parts, a target-specific binding region, a TCR-CD3 binding complex ligand, as well as a TCR co-receptor signaling region. For example, we have successfully generated several TAC constructs, including CD19 TAC, HER2 TAC, EGFR TAC, SOX TAC, as well as ROS1 TAC. The studies conducted by our labs have shown that these TAC-T cells can induce more efficient anti-tumor responses on targeted cells. It has increased anti-tumor efficacy, reduced toxicity, and faster tumor infiltration than other engineered T cells, such as CAR-T cells and TCR-T cells. As a result, we are committed to developing adoptive immunotherapy based on novel TAC-T cells to modulate the patient's immune system to recognize and fight cancer.
Fig.1 T Cell Antigen Connector (TAC) Technology.
Up to now, our TAC-T technology platform can provide various TAC-engineered T cell products to meet the unique needs of your research, like TAC-T cells and TAC lentivirus particles. We are attempting to establish our own TAC adoptive immunotherapy program. In our project, immune cells, usually T cells, are isolated and collected from the blood sample of tumor patients. These T cells will be modified by our unique TAC technology to recognize and kill specific tumor cells. The modified TAC-T cells will be amplified and injected back into the patient to target and kill cancer. Moreover, to provide safe and effective TAC adoptive immunotherapy, we are developed a panel of TAC-T-based analysis assays to ensure the quality and efficacy of TAC-T products, as well as to help establish high data acceptance criteria.
Fig.2 The Workflow of TAC Adoptive T Cell Therapy.
A blood sample can be collected from a tumor patient or allogeneic donors, and peripheral blood mononuclear cells (PBMCs) are separated and purified via density gradient centrifugation. Cell viability and expression of immune effector cell markers will be further analyzed.
Selection and utilization of appropriate targets are one of the keys to successful TAC adoptive T cell therapy. Normally, a large variety of tumor-associated antigens, such as CD19, HER2, and EGFR, have been broadly used for TAC antigen-binding domain design and preparation. For instance, scFvs derived from HER2 antibodies clone trastuzumab biosimilar, and pertuzumab biosimilar has been used for TAC-HER2 specific ligand generation. Furthermore, many viral vectors, such as lentivirus, retrovirus, adenovirus, herpes simplex virus I, or adeno-associated viruses, are used to transfer a specific tumor-antigen nucleic acid into T cells.
Fig.3 The Data Illustration of TAC-Mediated Adoptive T Cell Therapy in Solid Tumor Models.
Engineered TAC T-cells will be evaluated by a series of immunophenotyping and functional analysis assays for evaluating on-target efficacy or off-tumor activity. Commonly, in vitro assay systems are generally evaluated by using human cells, tissues, or positive/negative target expression cells, to help identify potential risks and reduce side effects to your candidate. In a recent study, flow cytometry assays have been conducted by testing viral infection efficiency by analyzing CD19 expression on the cell surface of CD4/CD8 positive T cells.
The appropriate animal models can provide support for predicting the effectiveness and specificity of a generated TAC model. In recent years, mouse models have made great strides in determining the efficacy of adoptive cell therapy products. Therefore, a variety of mouse models, such as transgenic, xenograft, or humanized, are also used by our scientists to evaluate the effectiveness and potential risks of TACs. In addition, the analysis of soluble protein factors is also very important for understanding the killing mechanism of TAC-T and the distribution of cytokines at different immunotherapy stages. In general, TAC-T-mediated cell killing should be assessed by using cell co-culturing assays (co-culture of target cells and TAC-T cells) to reveal the interaction between cancer cells and the immune system.
Creative Biolabs provides state-of-art services for any TAC-engineered T cells adoptive immunotherapy research. This novel TAC platform includes in-depth discovery chemistry and biology and aims to offer streamlined development services from TAC target identification to safety and toxicity studies. We have integrated high-quality TAC adoptive immunotherapy services based in the U.S. Our laboratory services have many advanced chemical and biological technologies to support customers' needs in the fast-growing TAC-engineered T cell adoptive immunotherapy research. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
For Research Use Only